Cipla Q3 profit rises about 7% to Rs401 crore
Cipla net profit rose to Rs401 crore in the third quarter ended 31 December, from Rs375 crore a year earlier
Bengaluru: Cipla Ltd, India’s fourth-largest drugmaker by revenue, said third-quarter net profit rose 7% on strong domestic sales, but fell short of analysts’ estimates.
Net profit attributable to shareholders climbed to Rs401 crore ($62.54 million) in the quarter ended on 31 December, from Rs375 crore a year earlier.
That compared with an average estimate of Rs444 crore in profit drawn from 18 analysts polled by Thomson Reuters I/B/E/S.
Including a one-off positive impact of Rs107 crore due to recalculation of deferred tax assets and liabilities on account of the tax reforms in the United States, profit rose about 25% from a year earlier, the company said.
Revenue from India, its biggest market, rose 15% to Rs1,601 crore. Domestic revenue accounted for more than a third of the total revenue, which rose 7% to Rs3,914 crore.
Revenue from North America fell 2% due to ongoing pricing pressures in the generics market because of increased competition.
At 2.29pm, Cipla shares were down 0.74% to Rs561.45 on BSE. Reuters
- Lenders accept ArcelorMittal resolution plan for Essar Steel
- #MeToo: Publicis India sacks executive creative director Ishrath Nawaz
- IFC launches $1 billion masala bond programme to aid India investments
- ICICI Securities reports 3.22% rise in Q2 profit at ₹134.22 crore
- Facebook hires Nick Clegg as head of global affairs
Editor's Picks »
- Policy rethink and higher volumes to aid container shippers
- DCB Bank delivers a strong Q2 but pressure on margins foreseen
- Havells India: Rising costs give a jolt to profitability in September quarter
- All’s well at Mindtree, except for high client concentration risk
- India’s rising steel demand is making companies starry-eyed